Status:
COMPLETED
Identification of Biomarkers for Early Detection of Pancreatic Cancer
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: Th...
Detailed Description
OBJECTIVES: * Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer. * Analyze serum proteins directly by mass spectrometry to identify new biom...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of pancreatic cancer
- Newly diagnosed disease
- Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00897494
Start Date
February 1 2005
End Date
April 1 2011
Last Update
March 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379